Many in the diabetes community view islet transplants to treat Type 1 diabetes as trading in one set of problems for another. While such transplants often restore the body’s insulin-producing and blood-sugar controlling abilities, they do not address the autoimmune component of the disease. Therefore, patients have to take immunosuppressant drugs, which slow the body’s attack on the transplanted islets but also open the patient to other sicknesses. (more…)
